FDA Approved: COSELA — Supplemental Application (G1 Therapeutics, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for COSELA (trilaciclib) from G1 Therapeutics, Inc., resulting in updated labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Cosela (trilaciclib)

Snippet

SUPPL AP for COSELA (TRILACICLIB)